China Biopharmaceutical (01177.HK): Key registration study on Class 1 innovative rovaxitinib tablets ROVADICITINIB (TQ05105) obtained positive results
Gelonghui, April 18 | China Biopharmaceutical (01177.HK) announced that the key registered clinical study of the Class 1 innovative drug Rovadicitinib (TQ05105), a class 1 innovative drug independently developed by the Group for the treatment of medium- and high-risk myelofibrosis (MF), has reached the main end. The Group has communicated with the Drug Evaluation Center (CDE) of the China National Drug Administration on the marketing application for TQ05105 tablets and obtained the CDE's approval to submit the marketing application for this product. The Group will submit a listing application for TQ05105 in the near future. TQ05105 is a group
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares
Sino Biopharmaceutical's (HKG:1177) employee benefit trust (EBT) has purchased 5 million of the firm's shares from the secondary market at about HK$2.459 apiece, according to a Wednesday filing with t
China Biopharmaceutical (01177.HK): Trustee buys 5 million shares under restricted share award scheme
Gelonghui, April 17, 丨 China Biopharmaceutical (01177.HK) issued an announcement. On April 17, 2024, the trustee purchased an additional 5 million shares from the market and held them in trust on behalf of the selected participants in accordance with the terms and conditions of the program rules.
Zhitong Hong Kong Stock Repurchase Statistics|April 17
Hong Kong Stock Repurchase Statistics|April 17
China Biopharmaceutical (01177) spent HK$12.7 million to buy back 5 million shares on April 16
China Biopharmaceutical (01177) announced that on April 16, 2024, the company spent HK$12.7 million...
[Broker Focus] Bank Securities first granted China Biopharmaceutical (01177) “Recommended” rating indicates that its innovative products have entered a period of performance harvesting
Jinwu Financial News | According to Bank Securities Research, in 2023, China Biopharmaceutical (01177) had total operating revenue of 26.376 billion yuan (-8.71% YoY, +0.7% YoY if Chia Dao Dao's revenue scale was excluded), and net profit to mother was 2.33 billion yuan (8.32% YoY). Since the launch of anlotinib, the core product of innovative drugs, in 2018, the company has established a comprehensive innovation and transformation strategy. Since then, the transformation has been accelerated through various methods. Currently, the company has a rich pipeline of innovative drugs, and its innovative business revenue continues to grow rapidly, successfully transforming from a pharmaceutical company with a focus on generic drugs to a first-tier innovative drug manufacturer. This line
China Biopharmaceutical (01177): Trustee buys an additional 5 million shares under the Restricted Share Award Program
China Biopharmaceutical (01177) issued an announcement. On April 15, 2024, the trustee made further purchases from the market...
China Galaxy Securities: Innovation and Transformation Accelerating the Harvest Period, First “Recommended” Rating for China Biopharmaceuticals (01177)
With the help of self-development+BD+ overseas platforms, China Biopharmaceutical (01177) has accelerated its innovation and transformation into a period of reaping performance.
China Biopharmaceutical (01177.HK): Trustee buys 7 million shares under restricted share award scheme
Gelonghui, April 12, 丨 China Biopharmaceutical (01177.HK) issued an announcement. On April 12, 2024, the trustee purchased an additional 7 million shares from the market and held them in trust on behalf of the selected participants in accordance with the terms and conditions of the program rules.
[Hong Kong Stock Connect] China Biopharmaceutical (01177) Releases Phase II Clinical Study Data on Non-small Cell Lung Cancer Drugs
Jinwu Financial News | China Biopharmaceutical (01177) announced that the KRAS G12C inhibitor “garsorasib (D-1553 tablets)” jointly developed by the Group has announced the latest results of the Phase II clinical trial (NCT05383898) at the 2024 American Cancer Association Annual Meeting (AACR) for non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The results of this study showed that garsorasib was objective in patients with locally advanced or metastatic NSCLC after anti-PD- (L) 1 treatment and platinum-containing chemotherapy
Sino Biopharmaceutical Presents Cancer Drug's Phase-II Clinical Trial Results at AACR 2024
Sino Biopharmaceutical (HKG:1177) presented Phase-II Clinical Trial results for its new drug for non-small cell lung cancer (NSCLC) at the annual meeting of the American Association for Cancer Researc
China Biopharmaceutical (01177.HK): KRAS G12C inhibitor “GARSORASIB (D-1553 tablets)” Phase II clinical study data released
Gelonghui, April 11 | China Biopharmaceutical (01177.HK) announced that the KRAS G12C inhibitor “garsorasib (D-1553 tablets)” jointly developed by the Group has announced the latest results of the phase II clinical trial (NCT05383898) at the 2024 American Cancer Association Annual Meeting (AACR) for non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations. The results of this study showed that in patients with locally advanced or metastatic NSCLC after anti-PD- (L) 1 treatment and platinum-containing chemotherapy, garso
China Biopharmaceutical (01177.HK): Anlotinib hydrochloride capsules, TQB2916 (CD40 agonist), and FHND6091 (proteasome inhibitor) were announced in 2024 AACR
Gelonghui, April 10 | China Biopharmaceutical (01177.HK) announced that the three innovative drugs “anlotinib hydrochloride capsules,” “TQB2916 (CD40 agonist),” and “FHND6091 (proteasome inhibitor)” developed by the group have announced 6 research results at the 2024 American Cancer Association Annual Meeting (AACR).
BOC International: Maintaining China Biopharmaceutical's “Buy” Rating Target Price of HK$4.8
BOC International released a research report stating that it maintains the “buy” rating of China Biopharmaceuticals (01177), with a target price of HK$4.8, and is optimistic that the 2024 performance recovery and the value of the innovation pipeline will continue to be realized. The company recently established a strategic partnership with Boehringer Ingelheim (BI). The bank believes that this cooperation will further consolidate the company's multi-target layout in the field of solid tumors, have strong collaboration with existing products, and increase the company's revenue and profits. BOB International's main views are as follows: Cooperation in the field of major oncology is highly collaborative with existing pipelines: the company recently established a strategic partnership with Boehringer Ingelheim (BI), and together
BOC International: Maintaining China Biopharmaceutical's (01177) “Buy” Rating Target Price of HK$4.8
BOB International believes that establishing a strategic partnership with Boehringer Ingelheim (BI) will further consolidate the multi-target layout of Mesosheng Pharmaceuticals in the field of solid tumors, have strong collaboration with existing products, and increase the company's revenue and profits.
[Broker Focus] BOC International maintains the purchase rating of Zhongsheng Pharmaceuticals (01177) and is optimistic that its performance will recover this year and that the value of the innovation pipeline will continue to be realized
Jinwu Financial News | According to the Bank of Commerce International Development Report, China Biopharmaceuticals (01177) recently established a strategic partnership with Boehringer Ingelheim (BI) to jointly develop and commercialize BI oncology pipelines in mainland China, including three assets in the clinical development stage, brigimadlin, ZongerTinib, and BI764532, as well as several innovative drug candidates in the early stages. Product revenue will be included in China Biopharmaceuticals' consolidated financial statements. The company estimates that the total peak sales of the three mid- to late-stage products in mainland China are expected to reach 5 billion yuan (203
Sino Biopharmaceutical Trustee Repurchases Shares
A trustee of Sino Biopharmaceutical (HKG:1177) bought back a further 6.8 million shares under its share award scheme for around HK$19.1 million or HK$2.83 apiece, a Monday filing on the Hong Kong bour
China Biopharmaceutical (01177): Trustee further purchases 6.75 million shares under the Restricted Share Award Program
China Biopharmaceutical (01177) issued an announcement. On April 8, 2024, the trustee purchased 6 more from the market...
Sino Biopharm and Boehringer Ingelheim Enter Into Strategic Collaboration
China Biopharmaceuticals (01177) and Boehringer Ingelheim establish a strategic partnership for innovative oncology product portfolios in China
China Biopharmaceutical (01177) announced that the group has established a strategic partnership with Boehringer Ingelheim to...
No Data